2 1 Shi Ji Jing Ji Bao Dao·2026-01-15 09:24Group 1 - Nvidia and Eli Lilly announced a collaboration to establish an AI joint innovation lab aimed at addressing challenges in the pharmaceutical industry using AI technology [2][3] - The lab will integrate Eli Lilly's expertise in drug discovery and development with Nvidia's strengths in AI and accelerated computing, with a joint investment of up to $1 billion over the next five years [2][4] - This partnership is expected to revolutionize existing drug development paradigms by combining large-scale data and scientific knowledge with advanced computational capabilities [2][4] Group 2 - The AI joint innovation lab will be located in the San Francisco Bay Area and will promote close collaboration between Eli Lilly's pharmaceutical experts and Nvidia's AI model engineers [3][4] - Initial focus will be on building a continuous learning system that connects Eli Lilly's smart wet lab with Nvidia's computational dry lab, enabling AI-assisted experiments [4] - Beyond drug discovery, the collaboration will explore AI applications in clinical development, manufacturing, and commercial operations [4] Group 3 - Eli Lilly has been actively pursuing partnerships in the AI pharmaceutical sector, including collaborations with Chinese AI companies and other major pharmaceutical firms [5][6] - The global AI pharmaceutical market is projected to reach between $28 billion and $53 billion, with significant growth expected in China's smart pharmaceutical industry [6][7] - The strategic shift towards AI in drug development is leading to increased capital interest and a transformation in how pharmaceutical companies approach AI solutions [7][8]